Welcome to NeurologyLive® Brain Games! This weekly quiz series, which goes live every Sunday morning, will feature questions ...
This episode, "Follow-Up Care and the Caregiver's Role in Managing Agitation," features the panel closing the series with a ...
Leonard Dragone, MD, PhD, Disease Area Leader at Johnson & Johnson, discusses how nipocalimab is being incorporated into generalized MG care, what long-term data show, and where J&J sees the therapy’s ...
Welcome to NeurologyLive® 's Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive 's widespread coverage in ...
Pivotal AFFINITY DUCHENNE results showed microdystrophin expression above the prespecified threshold in 93% of evaluable ...
A quick-read roundup of 10 late-breaking abstracts from the 2026 MDS Congress, from phase 3 Parkinson disease readouts to long-term data in Huntington disease and Tourette syndrome, with the key ...
The FDA has approved a once-daily autoinjector for zilucoplan (ZILBRYSQ), giving adults with generalized myasthenia gravis (gMG) a second self-administered delivery option for the ...
New analyses found differences in functional outcomes over 2 years among patients aged 8 to 12 years treated with ...
Three-year extension data from the phase 3 IB1001-301 trial show levacetylleucine slowed disease progression in both adults and children with Niemann-Pick disease type C.
On September 17, 2026, NeurologyLive convened a clinical forum in Philadelphia titled "Recognizing and Treating Plexiform ...
The FDA was busy in September 2026, issuing a number of decisions on potential new therapies, including approvals, clearances ...
How clinicians can turn everyday observations into publishable research: spotting the gap, choosing the right paper type, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results